Development and Evaluation of the Biological Adjuvant Bivalent Vaccine for Preventing Newcastle Disease and Infectious Bursal Disease

Figure 2

The identification of the recombinant viruses: (a) the identification of rClone30-VP2L-chGM-CSF virus by RT-PCR. Lane M: DL2000 marker, lane 1: rClone30-VP2L-chGM-CSF virus, and lane 2: negative control. (b) The identification of rClone30-VP2L virus by RT-PCR. Lane M: DL2000 marker, lane 1: rClone30-VP2L virus, and lane 2: negative control. (c) The identification of the recombinant viruses by Western blot. Lane M: prestained protein marker, lane 1: rClone30-VP2L-chGM-CSF virus, lane 2: rClone30-VP2L virus, lane 3: rClone30 virus, and lane 4: DMEM medium.

(a)

(b)

(c)